PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i6.13006ArticleCancer Cell Survival Strategies: The Collusion between Autophagy and Immune Evasion in Renal Cell Carcinomahttps://artdesignp.com/journal/PAR/9/6/10.26689/par.v9i6.13006DuYingwen,WangDanyun,ChenJiansen,XieJianxing,ChenMing,LinCanbin2025962025-12-10This review systematically elucidates the core mechanisms and research advancements regarding the role of autophagy in immune evasion in Renal Cell Carcinoma (RCC). Accumulating evidence indicates that autophagy exhibits a typical “context-dependent” dual role in RCC pathogenesis: it may suppress tumorigenesis in early stages, while primarily promoting cell survival and immunosuppressive functions within the established tumor microenvironment (TME). Autophagy facilitates immune escape through multi-dimensional mechanisms, including the precise regulation of PD-L1 stability, degradation of MHC-I molecules and the antigenic peptide pool, remodeling of the metabolic microenvironment, induction of T cell exhaustion, and enhancement of immunosuppressive cell functions. Therapeutically, combining autophagy inhibitors with immune checkpoint inhibitors has demonstrated significant synergistic effects in preclinical studies, and several clinical trials have provided preliminary validation of its safety and efficacy. Future research should focus on integrating multi-omics technologies and advanced disease models to deeply elucidate the autophagy regulatory network, explore its crosstalk with other cell death pathways such as pyroptosis and ferroptosis, and promote the development of personalized treatment strategies based on precise stratification of autophagy activity, thereby offering new avenues to overcome immunotherapy resistance in RCC.

Shen C, Hu G, Zhang S, et al., 2019, Immunophenotypic Characterization of Sphere-Forming Cells Derived From the Human Renal Cell Carcinoma Cell Line 786-O. Am J Transl Res, 10: 3978–3990.

Yin H, Cao Q, Zhao H, et al., 2019, Expression of CREPT Is Associated With Poor Prognosis of Patients With Renal Cell Carcinoma. Oncol Lett, 18: 4789–4797.

Wang J, Wen Q, Wang X, et al., 2022, Nomogram for Predicting Cancer-Specific Survival of Patients With Clear-Cell Renal Cell Carcinoma: A SEER-Based Population Study. Gen Physiol Biophys, 41: 591–601.

Bedke J, Ghanem Y, Albiges L, et al., 2025, Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma. European Urology, 87(4): 491–496.

Wang Z, Yan M, Ye L, et al., 2024, VHL Suppresses Autophagy and Tumor Growth Through PHD1-Dependent Beclin1 Hydroxylation. EMBO J, 43: 931–955.

Ribatti D, 2016, The Concept of Immune Surveillance Against Tumors. The First Theories. Oncotarget, 8: 7175–7180.

Altea-Manzano P, Decker-Farrell A, Janowitz T, et al., 2025, Metabolic Interplays Between the Tumour and the Host Shape the Tumour Macroenvironment. Nature Reviews Cancer, 25(4): 274–292.

Liao M, Yao D, Wu L, et al., 2024, Targeting the Warburg Effect: A Revisited Perspective From Molecular Mechanisms to Traditional and Innovative Therapeutic Strategies in Cancer. Acta Pharmaceutica Sinica B, 14(3): 953–1008.

Heravi G, Yazdanpanah O, Podgorski I, et al., 2022, Lipid Metabolism Reprogramming in Renal Cell Carcinoma. Cancer and Metastasis Reviews, 41(1): 17–31.

Zeng P, Lu W, Tian J, et al., 2022, Reductive TCA Cycle Catalyzed by Wild-Type IDH2 Promotes Acute Myeloid Leukemia and Is a Metabolic Vulnerability for Potential Targeted Therapy. Journal of Hematology & Oncology, 15(1): 30.

Lai Y, Tang F, Huang Y, et al., 2021, The Tumour Microenvironment and Metabolism in Renal Cell Carcinoma Targeted or Immune Therapy. Journal of Cellular Physiology, 236(3): 1616–1627.

Zhang Y, Zhang S, Sun H, et al., 2025, The Pathogenesis and Therapeutic Implications of Metabolic Reprogramming in Renal Cell Carcinoma. Cell Death Discovery, 11(1): 186.

Hervouet E, Simonnet H, Godinot C, 2007, Mitochondria and Reactive Oxygen Species in Renal Cancer. Biochimie, 89(9): 1080–1088.

Akbar A, Pandey S, Viswanathan P, 2025, The Role of E3 Ligases and Deubiquitinases in PD-L1 Regulation and the Tumor Microenvironment in Renal Cell Carcinoma. Medical Oncology, 42(9): 1–13.

Lin J, Sumara I, 2024, Cytoplasmic Nucleoporin Assemblage: The Cellular Artwork in Physiology and Disease. Nucleus, 15(1): 2387534.

Yu Y, Liang Y, Li D, et al., 2021, Glucose Metabolism Involved in PD-L1-Mediated Immune Escape in the Malignant Kidney Tumour Microenvironment. Cell Death Discovery, 7(1): 15.

Lemma E, Letian A, Altorki N, et al., 2023, Regulation of PD-L1 Trafficking From Synthesis to Degradation. Cancer Immunology Research, 11(7): 866–874.

Jin Y, Deng Z, Zhu T, 2022, Membrane Protein Trafficking in the Anti-Tumor Immune Response: Work of Endosomal-Lysosomal System. Cancer Cell International, 22(1): 413.

Liu K, Huang J, Liu J, et al., 2022, HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy. Cancer Research, 82(10): 2003–2018.

Radovanović M, 2021, Autophagy and Renal Cell Carcinoma: What Do We Know So Far? Medicinski Podmladak, 72(1): 43–49.

Wang ZL, Deng Q, Chong T, et al., 2018, Autophagy Suppresses the Proliferation of Renal Carcinoma Cell. European Review for Medical & Pharmacological Sciences, 22(2).

Mazumder S, Higgins P, Samarakoon R, 2023, Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers, 15(4): 1316.

Huang L, Wang L, Yuan D, et al., 2025, Overexpression of BNIP3 in Renal Carcinoma Cells Can Promote Apoptosis of Renal Carcinoma Cells Through HIF-1α-BNIP3-Mediated Autophagy. Frontiers in Oncology, 15: 1614378.

Taylor B, Balko J, 2022, Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Frontiers in Immunology, 13: 844866.

Mickley A, Kovaleva O, Kzhyshkowska J, et al., 2015, Molecular and Immunologic Markers of Kidney Cancer—Potential Applications in Predictive, Preventive and Personalized Medicine. EPMA Journal, 6(1): 20.

Saulle I, Vitalyos A, D’Agate D, et al., 2025, Unveiling the Impact of ERAP1 and ERAP2 on Migration, Angiogenesis and ER Stress Response. Frontiers in Cell and Developmental Biology, 13: 1564649.

Sari G, Rock K, 2023, Tumor Immune Evasion Through Loss of MHC Class-I Antigen Presentation. Current Opinion in Immunology, 83: 102329.

Béland D, Viens M, Kalin E, et al., 2025, From Oncogenesis to Prognosis: The Roles of the Immunoproteasome in Cancer. Frontiers in Immunology, 16: 1603816.

Bandopadhyay S, Patranabis S, 2023, Mechanisms of HIF-Driven Immunosuppression in Tumour Microenvironment. Journal of the Egyptian National Cancer Institute, 35(1): 27.

Jiang W, Jin W, Xu A, 2024, Cholesterol Metabolism in Tumor Microenvironment: Cancer Hallmarks and Therapeutic Opportunities. International Journal of Biological Sciences, 20(6): 2044.

Qin X, Denton W, Huiting L, 2020, Unraveling the Regulatory Role of Endoplasmic-Reticulum-Associated Degradation in Tumor Immunity. Critical Reviews in Biochemistry and Molecular Biology, 55(4): 322–353.

Lin P, Lin Y, Chen X, 2025, Decoding MHC Loss: Molecular Mechanisms and Implications for Immune Resistance in Cancer. Clinical and Translational Medicine, 15(7): e70403.

Ballesteros P, Chamorro J, Roman-Gil M, 2021, Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 13(23): 5981.

Goenka A, Khan F, Verma B, 2023, Tumor Microenvironment Signaling and Therapeutics in Cancer Progression. Cancer Communications, 43(5): 525–561.

Wu Q, Yu X, Li J, 2021, Metabolic Regulation in the Immune Response to Cancer. Cancer Communications, 41(8): 661–694.

Zhu H, Wang X, Lu S, 2023, Metabolic Reprogramming of Clear Cell Renal Cell Carcinoma. Frontiers in Endocrinology, 14: 1195500.

Gold L, Masson G, 2022, GCN2: Roles in Tumour Development and Progression. Biochemical Society Transactions, 50(2): 737–745.

Monjaras-Avila C, Lorenzo-Leal A, Luque-Badillo A, 2023, The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 24(9): 7946.

Zou Z, Tao T, Li H, 2020, mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Progress and Challenges. Cell & Bioscience, 10(1): 31.

Wang Y, Li J, Nakahata S, 2024, Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression. International Journal of Molecular Sciences, 25(13): 7346.

Wen H, Zheng S, Zhu X, 2025, Characteristics of the Tumor Microenvironment and Potential Immunotherapy Strategies in Renal Cell Carcinoma. Frontiers in Immunology, 16: 1643533.

Lei Y, Zhang E, Bai L, 2022, Autophagy in Cancer Immunotherapy. Cells, 11(19): 2996.

Liu H, Lv Z, Zhang G, 2024, Molecular Understanding and Clinical Aspects of Tumor-Associated Macrophages in the Immunotherapy of Renal Cell Carcinoma. Journal of Experimental & Clinical Cancer Research, 43(1): 242.

Bantug G, Hess C, 2023, The Immunometabolic Ecosystem in Cancer. Nature Immunology, 24(12): 2008–2020.

Fontecha-Barriuso M, Martin-Sanchez D, Martinez-Moreno J, 2020, The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases. Biomolecules, 10(2): 347.

Műzes G, Sipos F, 2023, Autoimmunity and Carcinogenesis: Their Relationship Under the Umbrella of Autophagy. Biomedicines, 11(4): 1130.

Castillo-Rodríguez R, Trejo-Solís C, Cabrera-Cano A, 2022, Hypoxia as a Modulator of Inflammation and Immune Response in Cancer. Cancers, 14(9): 2291.

Luo Y, Chang L, Ji Y, 2024, ER: A Critical Hub for STING Signaling Regulation. Trends in Cell Biology, 34(10): 865–881.

Pazhouhesh N, Hajiheidari M, Faghihkhorasani F, 2025, Breaking the Barriers: Overcoming Cancer Resistance by Targeting the NLRP3 Inflammasome. British Journal of Pharmacology, 182(1): 3–25.

Zahedi-Amiri A, Malone K, Beug S, 2021, Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. Cells, 10(10): 2672.

Ganini C, Montanaro M, Scimeca M, 2022, No Time to Die: How Kidney Cancer Evades Cell Death. International Journal of Molecular Sciences, 23(11): 6198.

Li D, Lei X, Zhao L, 2025, Mechanism of Action of HMGB1 in Urologic Malignancies. Frontiers in Oncology, 15: 1593157.

Liang X, Vera M, Buchser W, 2012, Inhibiting Systemic Autophagy During Interleukin 2 Immunotherapy Promotes Long-Term Tumor Regression. Cancer Research, 72(11): 2791–2801.

Zaarour R, Azakir B, Hajam E, 2021, Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. Cancers, 13(3): 533.

Sun W, Ma R, Zhao R, 2025, The NLRP3 Inflammasome in Urogenital Cancers: Structure, Dual Function, and Therapeutic Potential. Frontiers in Oncology, 15: 1593774.

Hashimoto S, Hashimoto A, Muromoto R, 2022, Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance. Cells, 11(16): 2618.

Bigos K, Quiles C, Lunj S, 2024, Tumour Response to Hypoxia: Understanding the Hypoxic Tumour Microenvironment to Improve Treatment Outcome in Solid Tumours. Frontiers in Oncology, 14: 1331355.

Hsu S, Li C, Lin I, 2021, Inflammation-Related Pyroptosis, a Novel Programmed Cell Death Pathway, and Its Crosstalk With Immune Therapy in Cancer Treatment. Theranostics, 11(18): 8813.

Wiwanitkit V, 2011, Renal Cell Carcinoma and Hepatitis C Virus Infection: Is There Any Cause-Outcome Relationship? Journal of Cancer Research and Therapeutics, 7(2): 226–227.

Lombardo D, Rossanese M, Musolino C, 2024, Parenchymal Renal Cell Carcinoma Is Associated With Occult Hepatitis B Virus Infection. Digestive and Liver Disease, 56: S30–S31.

Huang H, Peng J, Zhang J, 2011, YueF Overexpression Inhibits Cell Proliferation Partly through p21WAF1/Cip1 Upregulation in Renal Cell Carcinoma. International Journal of Molecular Sciences, 12(4): 2477–2487.

Silva L, Jung J, 2013, Modulation of the Autophagy Pathway by Human Tumor Viruses. Seminars in Cancer Biology, 23(5): 323–328.

Nesci S, Marchi S, Hu J, et al., 2025, Inflammatory Mitochondrial Signalling and Viral Mimicry in Cancer. Journal of Translational Medicine, 23(1): 982.

Sun B, Chen L, Fu H, et al., 2016, Upregulation of RICTOR Gene Transcription by the Proinflammatory Cytokines through NF-κB Pathway Contributes to the Metastasis of Renal Cell Carcinoma. Tumor Biology, 37(4): 4457–4466.

Feodoroff M, Hamdan F, Antignani G, et al., 2024, Enhancing T-Cell Recruitment in Renal Cell Carcinoma with Cytokine-Armed Adenoviruses. OncoImmunology, 13(1): 2407532.

Jones T, Carew J, Nawrocki S, 2020, Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. Cancers, 12(5): 1185.

Ballesteros P, Chamorro J, Román-Gil M, et al., 2021, Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 13(23): 5981.

Chen X, Lin P, Lu Y, et al., 2025, Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation. Advanced Science, 2025: e03095.

Lamsal A, 2023, Autophagy in Tissues and Solid Tumors Controlled by Infiltrating Immune Cells, thesis, Norwegian University of Science and Technology.

Miron R, Arildskov A, Bruun F, et al., 2022, What Genetics Can Do for Oncological Imaging: A Systematic Review of the Genetic Validation Data Used in Radiomics Studies. International Journal of Molecular Sciences, 23(12): 6504.

Lu J, Zhu L, Zheng L, et al., 2018, Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell Renal Carcinoma and the Antitumor Effects of SBI-0206965. EBioMedicine, 34: 85–93.

Saini S, Majid S, Dahiya R, 2011, The Complex Roles of Wnt Antagonists in RCC. Nature Reviews Urology, 8(12): 690–699.

Bresciani A, Spiezia M, Boggio R, et al., 2018, Quantifying Autophagy Using Novel LC3B and p62 TR-FRET Assays. PLOS One, 13(3): e0194423.

Wu Q, Wu Y, Zhang Y, et al., 2024, ImmunoPET/CT Imaging of Clear Cell Renal Cell Carcinoma with [18F] RCCB6: A First-in-Human Study. European Journal of Nuclear Medicine and Molecular Imaging, 51(8): 2444–2457.

Shi T, Yu X, Yan L, et al., 2017, Research Progress of Hydroxychloroquine and Autophagy Inhibitors on Cancer. Cancer Chemotherapy and Pharmacology, 79(2): 287–294.

Xu Q, Hu J, Wang Y, et al., 2025, The Role of Tumor Types in Immune-Related Adverse Events. Clinical and Translational Oncology, 27(8): 3247–3260.

Xiong B, Liu W, Liu Y, et al., 2024, A Multi-Omics Prognostic Model Capturing Tumor Stemness and the Immune Microenvironment in Clear Cell Renal Cell Carcinoma. Biomedicines, 12(10): 2171.

Wu Y, Chen R, Chiu H, et al., 2023, Nanoparticles Augment the Therapeutic Window of RT and Immunotherapy for Treating Cancers: Pivotal Role of Autophagy. Theranostics, 13(1): 40.

Angulo J, Manini C, López J, et al., 2021, The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers, 13(9): 2071.